Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Two Treatment, Two Period, Chronic Dosing (4 Weeks), Crossover, Multi-center Pilot Study to Evaluate the Effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Brief Summary: This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway dimensions.


Options:
A: Arm Label: fluticasone furoate/umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI) | Arm Label: umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Intervention Type: DRUG; Name: fluticasone furoate (FF); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: vilanterol (VI); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol, umeclidinium bromide/vilanterol | Intervention Type: DRUG; Name: umeclidinium bromide (UMEC); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, umeclidinium bromide/vilanterol
B: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Tiotropium + salmeterol/fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Salmeterol/fluticasone | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + salmeterol/fluticasone | Intervention Type: DRUG; Name: Salmeterol/fluticasone; Assigned to Arm(s): Tiotropium + salmeterol/fluticasone
C: Arm Label: BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: GFF MDI (PT003) 14.4/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) 14.4/9.6 μg | Arm Label: BFF MDI (PT009) 320/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI (PT009) 320/9.6 μg | Arm Label: Symbicort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator | Intervention Type: DRUG; Name: GFF MDI (PT003) 14.4/9.6 μg; Assigned to Arm(s): GFF MDI (PT003) 14.4/9.6 μg ex-actuator | Intervention Type: DRUG; Name: BFF MDI (PT009) 320/9.6 μg; Assigned to Arm(s): BFF MDI (PT009) 320/9.6 μg ex-actuator | Intervention Type: DRUG; Name: Symbicort® Turbuhaler® (TBH) Inhalation Powder; Assigned to Arm(s): Symbicort
D: Arm Label: BGF-GFF; Type: EXPERIMENTAL; Interventions: Combination Product: BGF, Combination Product: GFF | Arm Label: GFF-BGF; Type: EXPERIMENTAL; Interventions: Combination Product: BGF, Combination Product: GFF | Intervention Type: COMBINATION_PRODUCT; Name: BGF; Assigned to Arm(s): BGF-GFF, GFF-BGF | Intervention Type: COMBINATION_PRODUCT; Name: GFF; Assigned to Arm(s): BGF-GFF, GFF-BGF

Answer: D